UCB has announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA)."The FDA's approval of Cimzia® for the treatment of active PsA provides an additional, effective treatment option for those living with the condition.

Read more...